IFNG and tuberculosis: The MVA85A vaccine trial in humans demonstrated that despite robust induction of ‘multifunctional’ CD4+ T cells (producing IFN-γ, TNF and IL-2 cytokines), these immune responses did not translate to additional protection from TB compared to placebo vaccination (32).